Neurogene Inc. (NGNE)
NASDAQ: NGNEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NGNE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $458.53M
- EPS (TTM)
- -$5.03
- Dividend yield
- None
- 52-week range
- 15.93 – 43.66
- Day range
- 22.03 – 22.90
- Volume / Avg
- 178.26K / 307.78K
- Beta
- —
- Shares outstanding
- 20.70M
52-week range
NGNE stock today
On Nov 20, NGNE ended the session at $22.15, shedding $0.78 (3.40%), versus the S&P 500's 3.70% decline. At this level, NGNE sits in the middle of its 52-week range of $15.93 to $43.66: 49.3% below the high, set on Jul 9, 2026 and 39.0% above the low. NGNE is up 7.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 10.4%.
Neurogene has posted a net loss over the last twelve months (EPS of -$5.03), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Neurogene
Company profileNeurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Rachel L. McMinn Ph.D.
- Headquarters
- New York, NY
- Employees
- 131
- IPO year
- 2014
- Website
- neurogene.com
Financial highlights
Full financialsIn fiscal 2025, Neurogene generated $0 in revenue, down 100.0% from fiscal 2024, the first decline in the 14 years shown. Neurogene reported a net loss of $90.4 million, compared with a loss of $75.1 million a year earlier. Diluted earnings per share came in at -$4.24.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $925.00K | $0 | — | — |
| Growth | -100.00% | — | — | — | — |
| Net income | $-90.35M | $-75.14M | $-36.32M | $-55.19M | $-60.69M |
| EPS (diluted) | $-4.24 | $-4.28 | — | $-1.04 | $-1.10 |
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$77.63+250.47%
- Strong buy 1
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-1.05 vs $-1.49
- Surprise
- +29.53%
NGNE news
All NGNE newsNeurogene peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GYREGyre Therapeutics Inc. | 4.21 | -6.86% | $460.79M | vs NGNE |
| BLSMBlossomHill Therapeutics Inc. | 14.51 | +0.69% | $461.20M | vs NGNE |
| ASMBAssembly Biosciences Inc. | 22.19 | -1.38% | $454.39M | vs NGNE |
| STTKShattuck Labs Inc. | 4.46 | -1.98% | $454.22M | vs NGNE |
| RZLTRezolute Inc. | 3.92 | -6.67% | $465.58M | vs NGNE |
| MNPRMonopar Therapeutics Inc. | 69.00 | -1.84% | $467.60M | vs NGNE |
| EVOEvotec SE ADR | 1.32 | -8.97% | $469.11M | vs NGNE |
| KMDAKamada Ltd. | 7.74 | -1.15% | $446.85M | vs NGNE |
Indexes, lists and sector
Neurogene stock FAQ
What is Neurogene's stock price today?
NGNE last traded at $22.15 as of Nov 20, 4:00 PM EST, down 3.40% on the day. Prices are delayed at least 15 minutes.
Does Neurogene pay a dividend?
No. Neurogene does not currently pay a regular cash dividend.
Who is Neurogene's CEO?
Dr. Rachel L. McMinn Ph.D. is the chief executive officer of Neurogene Inc., which has about 131 employees.
Has NGNE ever split its stock?
Yes. The most recent NGNE stock split was a 1-for-4 split on Dec 19, 2023, one of 2 splits on record.
What is the NGNE 52-week high?
The 52-week high for NGNE is $43.66 and the 52-week low is $15.93. The stock is currently 49.3% below its high.